Protara Therapeutics, Inc. 8K

Protara Therapeutics announced Q1 2026 results and a pipeline update, including a planned 2H 2027 BLA for TARA-002 in lymphatic malformations, key NMIBC and IV Choline Chloride trial milestones in 2H 2026, and cash runway into 2028.

On May 13, 2026, Protara Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2026 and provided a comprehensive business update, highlighting plans to submit a Biologics License Application for TARA-002 in lymphatic malformations in the second half of 2027 following pivotal STARBORN-1 data, ongoing FDA engagement including transfer of review to the Office of Therapeutic Products, upcoming scientific presentations and a May 19, 2026 investor webinar on the LMs program, progress in its non-muscle invasive bladder cancer program with expected completion of enrollment in the BCG-unresponsive registrational cohort of the ADVANCED-2 trial and initiation of the ADVANCED-3 registrational trial in BCG-naive patients in the second half of 2026, continued advancement of the THRIVE-3 Phase 3 trial of IV Choline Chloride with interim data expected in the second half of 2026, and a strengthened liquidity position with $177.4 million in cash, cash equivalents and marketable debt securities expected to fund planned operations into 2028, alongside increased R&D and G&A expenses and a net loss of $17.8 million for the quarter.

Filing Facts

CIK

1359931

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-055462

Alert Tier

6